Journal
AMERICAN JOURNAL OF CLINICAL NUTRITION
Volume 118, Issue 3, Pages 507-517Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajcnut.2023.07.001
Keywords
visceral fat area; cancer; prognosis; nutritional status; body composition
Categories
Ask authors/readers for more resources
This study investigated the impact of adipose tissue indicators on the prognosis of cancer patients and found that visceral fat area (VFA) is a more effective indicator associated with higher risk of mortality in various types of cancer.
Background: Diverse indicators have been used to represent adipose tissue, while the relationship between body adipose mass and the prognosis of patients with cancer remains controversial. Objective: This study aimed to explore the indicators of optimal body composition that represent body fat mass to predict risk of cancer-related mortality. Methods: We conducted a population-based multicenter prospective cohort study of patients with initial cancer between February 2012 and September 2020. Clinical information, body composition indicators, hematologic test results, and follow-up data were collected. Body composition indicators were analyzed using principal component analysis to select the most representative indicators, and the cutoff value was set according to the optimal strati-fication method. The hazard ratio (HR) for mortality was calculated using Cox proportional hazards regression models. Results: Among 14,018 patients with complete body composition data, visceral fat area (VFA) is a more optimal indicator for body fat content (principal component index: 0.961) than body mass index (principal component index: 0.850). The cutoff points for VFA in terms of time to mortality were 66 cm2 and 102 cm2 for gastric/esophageal cancer and other cancers, respectively. Among the 2788 patients treated systemically, multivariate analyses demonstrated that a lower VFA was associated with a higher risk of death in patients with cancer of diverse types (HR: 1.33; 95% CI: 1.08, 1.64; P = 0.007), especially gastric cancer (HR: 2.13; 95% CI: 1.3, 3.49; P = 0.003), colorectal cancer HR: 1.81; 95% CI: 1.06, 3.08; P = 0.030) and nonsmall-cell lung cancer (HR: 1.27; 95% CI: 1.01, 1.59; P = 0.040). Conclusion: VFA is an independent prognostic indicator of muscle mass in patients with diverse types of cancer, particularly gastric, colorectal, and nonsmall-cell lung cancers. Trial registration number: ChiCTR1800020329.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available